All Outputs (4)

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition (2015)
Journal Article
Middleton, F. K., Patterson, M. J., Elstob, C. J., Fordham, S., Herriott, A., Wade, M. A., McCormick, A., Edmondson, R., May, F. E., Allan, J. M., Pollard, J. R., & Curtin, N. J. (2015). Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget, 6(32), 32396-32409. https://doi.org/10.18632/oncotarget.6136

ATR is an attractive target in cancer therapy because it signals replication stress and DNA lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the DNA damage response (DDR) may render cancer cells vulnerable to ATR inhibition alon... Read More about Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer (2015)
Journal Article
Jones, D., Wade, M., Nakjang, S., Chaytor, L., Grey, J., Robson, C. N., & Gaughan, L. (2015). FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget, 6(30), 29782-29794. https://doi.org/10.18632/oncotarget.4927

Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the requirement for the development of more effective AR targeting therapies. A key mechanism of resistance to anti-androgens is through expression... Read More about FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy (2015)
Journal Article
O’Neill, D., Jones, D., Wade, M., Grey, J., Nakjang, S., Guo, W., Cork, D., Davies, B. R., Wedge, S. R., Robson, C. N., & Gaughan, L. (2015). Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget, 6(28), 26029-26040. https://doi.org/10.18632/oncotarget.4347

The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection o... Read More about Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

Does radiation-induced c-MYC amplification initiate breast oncogenesis? (2015)
Journal Article
Wade, M. A., May, F. E., Onel, K., & Allan, J. M. (2016). Does radiation-induced c-MYC amplification initiate breast oncogenesis?. Molecular and Cellular Oncology, 3(1), Article e1010950. https://doi.org/10.1080/23723556.2015.1010950

© 2016 Taylor and Francis Group, LLC. The MYC (v-myc avian myelocytomatosis viral oncogene homolog; c-MYC) locus on chromosome 8q is susceptible to high-level amplification following exposure of human breast cells to ionizing radiation, and c-MYC amp... Read More about Does radiation-induced c-MYC amplification initiate breast oncogenesis?.